A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive

PHASE2CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

August 14, 2023

Study Completion Date

August 14, 2023

Conditions
Coronavirus Disease-2019 (COVID-19) Prevention
Interventions
BIOLOGICAL

Ad26.COV2.S

Ad26.COV2.S will be administered as intramuscular (IM) injection.

Trial Locations (18)

152

Setshaba Research Centre, Soshanguve

1864

Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto

2001

Shandukani Research Centre, Johannesburg

2092

University of Witwatersrand - Helen Joseph Hospital - Themba Lethu Hiv Research Centre, Westdene Johannesburg Gauteng

4000

Hospital del Niño Jesús, San Miguel de Tucumán

5000

Hospital de Ninos de Cordoba, Córdoba

64460

Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey

395009

BAPS Pramukhswami Hospital, Surat

570004

JSS Hospital, Mysore

600116

Sri ramchandra Medical College & Research Institute, Chennai

C1119ACN

CIPREC, Buenos Aires

30130-100

Universidade Federal De Minas Gerais - Hospital das Clínicas, Belo Horizonte

30150-221

Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte

14051-140

Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP, Ribeirão Preto

01228-000

CPQuali Pesquisa Clinica LTDA ME, São Paulo

0422002

Supe Heart And Diabetes Hospital and Research Center, Nashik

06760

CAIMED Investigacion en salud S.A de C.V., Mexico City

0485

Ndlovu Elandsdoorn Site, Dennilton

All Listed Sponsors
lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT05007080 - A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive | Biotech Hunter | Biotech Hunter